Oral thrombostatin FM19 inhibits prostate cancer

Marvin T. Nieman; Gretchen A. LaRusch; Chao Fang; Yihua Zhou; Alvin H. Schmaier

doi:10.1160/TH09-08-0570

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2010; 104(05): 1044-1048
DOI: 10.1160/TH09-08-0570

Cellular Proteolysis and Oncology

Schattauer GmbH

Oral thrombostatin FM19 inhibits prostate cancer

Authors

Marvin T. Nieman

¹Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
Gretchen A. LaRusch

¹Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
Chao Fang

¹Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
Yihua Zhou

¹Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
Alvin H. Schmaier

¹Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA

Abstract

Summary

Thrombin stimulates proliferation, invasion and metastasis by cleaving protease-activated receptor 1 (PAR1) on human prostate cancer cells. Current direct thrombin inhibitors pose risks for bleeding in the cancer patients. We have developed an oral reversible direct thrombin inhibitor called FM19. FM19 inhibits thrombin-induced calcium mobilisation of PC3 cells with an IC₅₀ of 15 μM with a 95% confidence interval of 7.3–31.6 μM. Thrombin stimulation increases PC3 cell invasion threefold from 27.1 ± 11.4 to 66 ± 11.6. FM19 or bivalirudin reduces cell invasion at ≥0.1 μM (p≤0.02). After inoculation with PC3 cells, nude mice were treated with oral FM19 at 3 mg/ml in the drinking water. The treated mice did not have long bleeding times and only a 1.4-fold increase in their thrombin clotting time. However, with treatment, the mice have a reduced rate of tumour growth 0.26 ± 0.17 fold change/day vs. 0.55 ± 0.35 for untreated (p = 0.038), reduced fold change in tumour size 5.3 ± 0.47 to 8.9 ± 1.8 (untreated) (p=0.048), and reduced overall tumour weight 0.5 ± 0.31 g vs. 0.82 ± 0.32 g (untreated) (p=0.04). On microscopic examination, FM19 treatment reduces the number of large vessels in the tumours from 4.6 ± 2.1 per high-powered field in untreated samples to 1.4 ± 1.4 in treated samples (p≤0.04). These studies show FM19 reduces prostate tumour growth in vivo at a concentration below that needed for anticoagulation. These data suggest novel opportunities for oral direct thrombin inhibitors in cancer therapy.

Keywords

Prostate cancer - oral direct thrombin inhibitor - anticoagulation - cancer treatment

Full Text

References

References
1 Sanders RJ, Mainiero F, Giancotti FG. The role of integrins in tumorigenesis and metastasis. Cancer Invest 1998; 16: 329-344.
2 Schnitzer JE. Vascular targeting as a strategy for cancer therapy. N Engl J Med 1998; 339: 472-474.
3 Hu L, Ibrahim S, Liu C. et al. Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222. Cancer Res 2009; 69: 3374-3381.
4 Hu L, Lee M, Campbell W. et al. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 2004; 104: 2746-2751.
5 Chay CH, Cooper CR, Gendernalik JD. et al. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 2002; 60: 760-765.
6 Tantivejkul K, Loberg RD, Mawocha SC. et al. PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem 2005; 96: 641-652.
7 Liu J, Bastian M, Kohlschein P. et al. Expression of functional protease-activated receptor 1 in human prostate cancer cell lines. Urol Res 2003; 31: 163-168.
8 Yuan TC, Lin MF. Protease-activated receptor 1: a role in prostate cancer metastasis. Clin Prostate Cancer 2004; 03: 189-191.
9 Kaushal V, Kohli M, Dennis RA. et al. Thrombin receptor expression is upregulated in prostate cancer. Prostate 2006; 66: 273-282.
10 Yin YJ, Salah Z, Maoz M. et al. Oncogenic transformation induces tumor angio-genesis: a role for PAR1 activation. FASEB J 2003; 17: 163-174.
11 Yin YJ, Salah Z, Grisaru-Granovsky S. et al. Human protease-activated receptor 1 expression in malignant epithelia: a role in invasiveness. Arterioscler Thromb Vasc Biol 2003; 23: 940-944.
12 Wojtukiewicz MZ, Tang DG, Ciarelli JJ. et al. Thrombin increases the metastatic potential of tumor cells. Int J Cancer 1993; 54: 793-806.
13 Nierodzik ML, Chen K, Takeshita K. et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998; 92: 3694-3700.
14 Kamath L, Meydani A, Foss F. et al. Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res 2001; 61: 5933-5940.
15 Shi X, Gangadharan B, Brass LF. et al. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004; 02: 395-402.
16 Salah Z, Maoz M, Cohen I. et al. Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression. FASEB J 2005; 19: 62-72.
17 Salah Z, Maoz M, Pizov G. et al. Transcriptional regulation of human protease-activated receptor 1: a role for the early growth response-1 protein in prostate cancer. Cancer Res 2007; 67: 9835-9843.
18 Hasan AA, Warnock M, Nieman M. et al. Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin. Am J Physiol Heart Circ Physiol 2003; 285: H183-H193.
19 Nieman MT, Warnock M, Hasan AA. et al. The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of pro-tease-activated receptor 1. J Pharmacol Exp Ther 2004; 311: 492-501.
20 Burke FM, Warnock M, Schmaier AH. et al. Synthesis of novel peptide inhibitors of thrombin-induced platelet activation. Chem Biol Drug Des 2006; 68: 235-238.
21 Nieman MT, Burke F, Warnock M. et al. Thrombostatin FM compounds: direct thrombin inhibitors – mechanism of action in vitro and in vivo. J Thromb Haemost 2008; 06: 837-845.
22 Schneider A, Kalikin LM, Mattos AC. et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005; 146: 1727-1736.
23 Johnson ML, Faunt LM. Parameter estimation by least-squares methods. Methods Enzymol 1992; 210: 1-37.
24 Beechem JM. Global analysis of biochemical and biophysical data. Methods Enzymol 1992; 210: 37-54.
25 Yuasa H, Amidon GL, Fleisher D. peptide carrier-mediate transport in interstinal brush border membrane vesicles of rats and rabbits: cephradine uptake and inhibition. Pharm Res. 1993; 10: 400-404.